Myotonia
6
1
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
50%
3 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
Electromyostimulation (EMS) of Astronauts in Spaceflight (Easymotion-2)
Global Study of Del-desiran for the Treatment of DM1
An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR
Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia
Cardiovascular Consequences of NIV Withdrawal in Patients With Myotonic Dystrophy